Scrip
The Medicines Company to pay up to $420 million for discontinued Pfizer CV candidate
23 December 2009
Christopher Spillane
The Medicines Company has handed the potential anti-atherosclerotic ApoA-I Milano a new lease of life after acquiring the candidate from
Pfizer for up to $420 million. The product's development had been abandoned and was unlikely to be revived under Pfizer's current strategy.
The product joined...
Please Login to read the full article.
23 December 2009
Christopher Spillane
The product joined...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Cerenis's CER-001 heading for Phase II with €51 million in new funds
- FDA safety official again attacks Avandia safety - with new CV risk data in the elderly
- SemBioSys touts its ApoA-I Milano product in wake of Pfizer deal
- Celgene to acquire Abraxis Bioscience for $2.9 billion up front
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
